抗乙型肝炎病毒药物筛选评价体系的建立及肝康栓抗乙型肝炎病毒的实验研究
|
摘要
【目的】
建立一套检测乙型肝炎病毒基因的Taqman探针实时荧光定量PCR系统、分别利用HepG2．2．15细胞模型和鸭乙型肝炎模型于体外、体内研究乙型肝炎病毒，从而建立并完善抗乙型肝炎病毒药物筛选、评价体系。并利用该体系评价肝康栓体内、外抗乙型肝炎病毒的作用。
【方法】
1．根据病毒基因组和核苷酸序列特点，分别设计3对特异性引物及Taqman探针。利用这3对引物分别扩增HBV DNA、DHBV DNA及DHBV cccDNA目的基因片段。PCR产物纯化、回收后，克隆入pUCm-T载体，转化DH5α菌株，筛选阳性菌落，提取重组质粒。重组质粒经PCR及测序鉴定后，用于制备实时荧光定量PCR的标准品和绘制标准曲线。通过优化反应体系和循环参数，建立乙型肝炎病毒基因Taqman探针实时荧光定量PCR检测系统。并进一步评价该系统的灵敏度、特异度及可重复性。
2．体外培养HepG2．2．15细胞，观察该细胞培养1、2、4、6、8、10、12、14天时的生长情况和HBsAg、HBeAg的分泌情况。用MTT法检测肝康栓和拉米夫定对HepG2．2．1 5细胞的细胞毒性作用，计算肝康栓和拉米夫定的半数中毒浓度。并分别用ELISA法或PCR法检测肝康栓(12mg／ml、10mg／ml、6mg／ml和5mg／ml的终浓度)与拉米夫定(0．2μg／ml、1μg／ml、5μg／ml和25μg／ml的终浓度)作用4、7、10天时，HepG2．2．15细胞培养上清液中HBsAg、HBeAg、HBV DNA的抑制作用。计算培养第10天时肝康栓和拉米夫定抑制HepG2．2．15细胞上清液中HBsAg、HBeAg分泌及HBV DNA复制的半数有效浓度。最后评价肝康栓的选择指数。
3．分别提取244份武汉地区成年樱桃谷鸭血清中的DHBV DNA，并进行PCR扩增和琼脂糖凝胶电泳。估计武汉地区成年樱桃谷鸭DHBV携带率。取1日龄樱桃谷雏鸭96只，利用PCR法筛选先天DHBV DNA(-)雏鸭用于制备动物模型，并估计樱桃谷雏鸭DHBV自然感染率。通过胫静脉注射DHBVDNA强阳性血清(0．2ml／只)，利用先天DHBV DNA(-)雏鸭制备后天感染鸭乙型肝炎病毒动物模型，并计算DHBV造模感染率。
4．采用正常樱桃谷雏鸭研究肝康栓短期毒性反应。将后天感染鸭乙型肝炎病毒动物模型雏鸭随机分为：模型对照组，ACV对照组，大、中、小剂量肝康栓治疗组，每组12只；再取12只2周龄的正常雏鸭作为正常对照组。分别于第一次给药前(T_0)、给药14d(T_(14))、给药28d(T_(28))和停药7d(P_7)时，胫静脉取血(0．5ml／只)，分离血清，检测肝康栓对雏鸭血清中DHBVDNA的抑制情况和血清ALT、AST的影响。并于停药7d时将各组鸭处死，统一取肝右叶2块组织，分别用于检测肝脏DHBV DNA、DHBVcccDNA和组织病理学。
【结果】
1．本实验成功构建了pUCm-HBV DNA、pUCm-DHBV DNA和pUCm-DHBVcccDNA三种质粒标准品。在(1×10~2～1×10~9)copies／ml浓度范围内，三种标准品的含量与Ct值的相关系数r分别为-1．00、-0．999和-0．997。(5×10~3～5×10~8)copies／ml 6个浓度的三种质粒标准品，在同一实时荧光定量PCR仪上重复进行4次扩增，Ct值的变异系数均小于5％。利用本实验所建立的Taqman探针实时荧光定量PCR系统检测HBV DNA、DHBV DNA和DHBV cccDNA的灵敏度分别为：5×10~1 copies／ml、5×10~1 copies／ml和1×10~2copies／ml；并且HBV DNA阳性上清液、DHBV DNA阳性鸭血清和DHBV cccDNA阳性鸭肝组织用本法检测均出现阳性扩增，而空白的培养基、正常鸭血清及正常鸭肝组织均未出现阳性扩增。
2．①HepG2．2．15细胞按1×10~6／L浓度接种、培养后，第8～12天细胞生长状态最佳；并且用ELISA法检测培养上清发现培养1天后，检测细胞上清液中的HBsAg和HBeAg均为阳性，其后培养上清液中HBsAg及HBeAg的分泌量随着培养时间的增长而逐渐增加，在培养第10天达到高峰。培养第1-6天时HBsAg分泌增长速度较HBeAg快；但是整个培养过程中，HBeAg分泌量均高于同时期HBsAg的分泌量。
②肝康栓在(7．5～60)mg／ml浓度范围内，对HepG2．2．15细胞增殖的抑制作用随肝康栓的浓度增加而增强，当肝康栓浓度小于15mg／ml时，对细胞增殖的抑制率＜20%。
③12mg／ml的肝康栓作用10天后，HBsAg、HBeAg的抑制率达最大，分别为68．2％和62．7％。呈明显的时间和剂量依赖性；而3TC在25μg／ml浓度下作用7天，HBsAg、HBeAg的抑制率最大，分别为50．1％和47．3％。且3TC培养10天时，HBsAg、HBeAg的抑制率均较培养7天时减弱。无明显的时间依赖性。
④肝康栓在12mg/ml浓度、作用10天时，对HepG2．2．15细胞上清中HBV DNA的抑制率较强，为78．8％；而3TC在25μg／ml浓度、作用10天时，对HepG2．2．15细胞上清中HBV DNA的抑制率最强，为97．9%。
⑤肝康栓和3TC抑制HBV DNA的选择指数分别为6．14和31450．5。
3．在244份武汉地区采集的成年樱桃谷鸭血清标本中，52份为DHBV DNA阳性血清，估计武汉地区成年樱桃谷鸭DHBV携带率为：[16．64％～26．87%](95％置信区间)。而96只1日龄樱桃谷雏鸭中，在接种前检测DHBV DNA，只有11只为DHBV DNA阳性，估计樱桃谷雏鸭DHBV自然感染率为[6．52％～19．36%](95％置信区间)。随机选取1日龄DHBV DNA(-)的樱桃谷雏鸭80只，接种DHBV DNA强阳性血清1周后，69只为DHBV DNA阳性，8只为阴性，3只死亡，DHBV造模感染率为86．25%。
4．①肝康栓大、中、小剂量组雏鸭给药前、给药7天、给药14天、给药28天时，与对照组雏鸭相比，在羽毛色泽，步态，进食状况，精神状态，对刺激的反应等方面也均无明显差异；各组雏鸭在试验各阶段，体重及体重增重值均无统计学差异(p＞0．05)。
②肝康栓大剂量组雏鸭血清DHBV DNA始终低于同期其他组，且在停药7天时下降至最低(p＜0．01)；肝康栓大、中剂量组在停药7天后DHBV DBA均未出现反弹，而肝康栓小剂量组及ACV对照组均有不同程度的反弹。
③停药7天时，肝康栓大剂量组雏鸭肝组织DHBV DNA和DHBV cccDNA均受明显抑制，结果有统计学意义(p＜0．05)。
④与同期模型组比较，肝康栓中、大剂量组雏鸭在治疗28天和停药7天时血清ALT明显降低，有显著差异(p＜0．01)。肝康栓大剂量组雏鸭在治疗14天时血清AST也明显降低，有显著差异(p＜0．05)；与同期ACV对照组比较，肝康栓大剂量组在给药28天时，血清ALT明显降低，有显著差异(p＜0．05)。停药7天时，肝康栓中、大剂量组ALT也明显降低，有显著差异(p＜0．05)。而ACV对照组在治疗过程中ALT、AST均未见显著下降。
⑤肝组织病理检查结果显示：肝康栓小、中、大剂量组与模型组相比，汇管区炎性细胞浸润和肝细胞点、灶状坏死均有不同程度的改善。其中肝康栓大、中剂量组改善较为明显。
【结论】
1．本实验成功构建了一套检测乙型肝炎病毒基因的Taqman探针实时荧光定量PCR系统，并且通过方法学评价该系统具有很好的灵敏度、特异度和可重复性。基本建立了一套较完善的抗乙型肝炎病毒药物筛选、评价体系。
2．培养第8～12天的HepG2．2．15细胞处于生长高峰期，在此期进行药物实验较适宜。肝康栓体外实验的细胞毒性较小，并且对HepG2．2．15细胞培养上清液中HBsAg、HBeAg及HBV DNA有一定的抑制作用。
3．武汉地区成年樱桃谷鸭的DHBV携带率不高，其雏鸭DHBV自然感染率较低，适用于制备感染DHBV的鸭乙型肝炎动物模型。并且在本研究中成功制备了后天感染DHBV的樱桃谷雏鸭模型。
4．肝康栓对雏鸭无明显短期毒性作用，初步提示肝康栓作为治疗慢性乙型肝炎的药物是安全的。肝康栓能抑制模型雏鸭血清中的DHBV DNA，且存在一定的剂量和时间依赖性。肝康栓能有效抑制模型雏鸭肝组织中的DHBV DNA和DHBV cccDNA。肝康栓还能改善雏鸭的血清生化学和肝组织病理学。我们认为这些作用除了与肝康栓能有效抑制DHBV DNA的复制外，还与其组方中的有效成分(甘草甜素、香菇菌多糖)有关。这也充分显示了肝康栓作为复方制剂治疗慢性乙型肝炎的优势。
【Objective】
To establish a real-time fluorescent quantitation PCR system using Taqman probe fordetecting hepatitis B virus gene.The HepG2.2.15 cell strain and duck hepatitis B animalmodel were used to study hepatitis B virus respectively in vitro or in vitro.Accordingly,thescreening-evaluation system for anti-hepatitis B virus drugs was established.The effect ofGankang Suppository on hepatitis B virus in vitro and in vivo was studied utilizing thissystem.
【Methods】
1.According to the characters of viral genome and nucleotide sequence,3 special primerpairs and Taqman probe were designed.The target gene fragments of HBV DNA、DHBVDNA and DHBV cccDNA were amplified and were cloned in pUCm-T vector after PCRproducts purification and gel extraction,and the plasmids were transformed into DH5αstrains.The recombinant plasmids evaluated by PCR and sequencing were prepared for standardsubstance and standard curve of real-time quantitation PCR.Optimizing the reaction systemand parameter,the real-time fluorescent quantitation PCR system using Taqman probe fordetecting hepatitis B virus gene was established.The sensibility,specificity and repeatabilityof this system were estimated.
2.The growth status and HBsAg、HBeAg secretion of HepG2.2.15 were observed afterculturing 1、2、4、6、8、10、12、14d.The cytotoxic effect of Gankang Suppository and lamivudine were detected by MTT assay,and the 50% Toxic Concentrations wereaccounted.The HBsAg、HBeAg、HBV DNA in supernate were detected by ELISA and PCRon 4~(th)、7~(th)、10~(th)day after adding Gankang Suppository (12mg/ml、10mg/ml、6mg/ml and5mg/ml)and lamivudine (0.2μg/ml、1μg/ml、5μg/ml and 25μg/ml).The 50% EffectiveConcentration and Selection Index of Gankang Suppository and lamivudine to HBsAg、HBeAg、HBV DNA in supernate on 10~(th)day were accounted.
3.The DHBV DNA extracted from 244 serum of adult Yingtao Gu duck in Wuhan wasdetected by PCR and agarose gel electrophoresis and the DHBV DNA positive rate wasestimated.The congenital DHBV DNA(-)ducklings picked from 96 Yingtao Gu ducklingsby PCR were used to prepared animal model and the DHBV natural infection rate of YingtaoGu ducklings was also estimated.The method of DHBV DNA positive serum injection(0.2ml)via vena cruralis was used to prepare postnatal infection duck hepatitis B virus animal model,and the DHBV infection rate was accouted.
4.The normal Yingtao Gu ducklings were used to study short term toxicity effect ofGankang Suppository.The ducklings of postnatal infectious duck hepatitis B virus weredivided randomly to:control group,ACV control group,Gankang Suppository large-dosegroup、medium-dose group、small-dose group,(12 ducklings in every group),and 12 twoweeks old normal ducklings were selected for normal control group.The DHBV DNA,ALTand AST were respectively detected before treatment (T_0),14 days (T_(14))and 28 days (T_(28))after treatment,and 7 days after withdrawal (P_7).The histopathological change,DHBV DNA,and DHBV cccDNA of liver tissue was observed 7 days after withdrawal.
【Results】
1.The three standard substances of pUCm-HBV DNA、pUCm-DHBV DNA andpUCm-DHBV cccDNA were successfully constructed.In the range of (1×10~2～1×10~9)copies/ml,the coefficient correlation (r)of these standard substances content to Ct were:-1.00,-0.999 and-0.997 respective.In the range of (5×10~3～5×10~8)copies/ml,the Ct coefficient of variability of these standard substances were all less than 5%,which weredetected repetitively for 4 times in the same instrument for real-time PCR.The sensibilities ofdetecting HBV DNA,DHBV DNA and DHBV cccDNA used this real-time fluorescentquantitation PCR system were 5×10~1copies/ml、5×10~1copies/ml and 1×10~2copies/ml.Thepositive amplification was detected in HBV DNA positive supernate,DHBV DNA positiveduck serum and DHBV cccDNA positive hepatic tissue,conversely in blank culture media,normal duck serum and hepatic tissue.
2.①HepG2.2.15 cell growth best on 8~(th)-12~(th)day after microbiomation.The HBsAg andHBeAg in supernate were positive on 1st day,and the secretory volume of HBsAg andHBeAg increased gradually along with culture time lapsing,and achieved peak on 10~(th)day.Even though the increasing velocity of HBsAg secretory volume bigger than HBeAg in 1~(st)-6~(th),the secretory volume of HBeAg always more than HBsAg in the same period duringwhole culture.
②In the range of (7.5～60)mg/ml Gankang Suppository,the inhibitory effect toHepG2.2.15 cell multiplication enhanced gradually along with drug concentration increasing.And when the concentration of Gankang Suppository was small than 15mg/ml,the inhibitoryrate of HepG2.2.15 cell multiplication was small than 20%.
③The inhibitory rate of HBsAg and HBeAg on 10th day after adding 12mg/mlGankang Suppository were the greatest:68.2% and 62.7%.It showed apparent time and dosedependent.And the inhibitory rate of HBsAg and HBeAg on 7~(th)day after adding 25μg/ml3TC were the greatest:50.1% and 47.3%,and the inhibitory rate of HBsAg and HBeAg on10~(th)day was lower than that on 7~(th)day,and did not show time and dose dependent.
④The inhibitory rate of HBV DNA of supernate was greatest (78.8%)on 10~(th)day afteradding 12mg/ml Gankang Suppository.However,The inhibitory rate of HBV DNA ofsupernate was greatest (97.9%)on 10~(th)day after adding 25μg/ml 3TC.
⑤The selection index of Gankang Suppository and 3TC were 6.14 and 31450.5.
3.There were 52 DHBV DNA positive sera in 244 sera of adult Yingtao Gu duck collected in Wuhan,and the DHBV DNA positive rate in adult Yingtao Gu duck was[16.64%～26.87%] (95% confidence intervals).There were only 11 DHBV DNA positiveducklings in 96 one day old Yingtao Gu ducklings,detected before injecting DHBV DNAserum.The DHBV DNA natural infection rate of Yingtao Gu ducklings was [6.52%～19.36%] (95% confidence intervals).In 80 one day old Yingtao Gu ducklings randomselected to prepare model,69 ducklings were DHBV DNA positive after 1 week of injectingDHBV DNA positive serum.The DHBV infectious rate was 86.25%.
4.①Before treatment,7 days,14 days and 28 days after treatment,no significantdifferences were found among the Gankang Suppository large-dose group、medium-dosegroup、small-dose group and control group,in terms of feather color/luster,gait,food-taking,mental status and response to stimuli,and no significant differences were found among everygroups in every experimental stages,in terms of body weight and weight gain.(P＞0.05)
②The DHBV DNA level in Gankang Suppository large-dose group was always lowerthan other groups in the same stage,and it descended to the minimum on P_7 (P＜0.01).TheDHBV DNA level in Gankang Suppository large-dose group and medium-dose group had notrebounded on P_7,however,the DHBV DNA level in Gankang Suppository small-dose groupdid not rebound had rebounded.
③The DHBV DNA and DHBV cccDNA of hepatic tissue in the Gankang Suppositorylarge-dose group had significantly decreased on P_7(P＜0.05).
④Compared with model control group,the ALT values of Gankang Suppositorylarge-dose group、medium-dose group were significantly lower on T_(28)and P_7 (P＜0.01),andthe AST value in Gankang Suppository large-dose group was also significantly lower on T_(14)(P＜0.05).Compared with ACV group,the ALT level of Gankang Suppository large-dosegroup had significantly decreased at T_(28)(P＜0.05),and the ALT level of Gankang Suppositorylarge-dose group,medium-dose group had significantly decreased at P_7(P＜0.05).However,the ALT and AST level of ACV control group had not significantly decreased during thewhole treatment.
⑤Histopathological examination of the liver showed:Compared with DHBV modelcontrol group,the inflammatory cell infiltrate and necrosis in Gankang Suppositorylarge-dose group,medium-dose group and small-dose group were all alleviated,especially inlarge-dose group and medium-dose group.
【Conclusion】
1.In the study,a real-time fluorescent quantitation PCR system using Taqman probe fordetecting hepatitis B virus gene was successfully established,and sensibility,specificity andrepeatability of this system were very well estimated by methodology.A screening-evaluationsystem for anti-hepatitis B virus drugs was established in principle.
2.The drug study was condign to carry out on 8~(th)-10~(th)of HepG2.2.15 cell culture,inwhich phase the cell was in summit of growth.The cytotoxicity of Gankang Suppository wasslight in vitro,and it can inhibit the secretion of HBsAg、HBeAg and HBV DNA certainly.
3.The Yingtao Gu duckling was applied to prepare duck hepatitis B animal model byDHBV injection,because the DHBV infection rate in Yingtao Gu duck in Wuhan and theDHBV natural infection rate in the duckling were both low.The Yingtao Gu ducklinghepatitis B model infected postnatal DHBV was successfully prepared.
4.Gankang Suppository had no obvious short-term toxicity to ducklings,it prompted thatGankang Suppository is safe for treating hepatitis B.It was dose and time dependent thatGankang Suppository inhibited the DHBV DNA level in model ducklings.GankangSuppository could effectively suppress the DHBV DNA and DHBV cccDNA in hepatic tissue.Gankang Suppository could also improve the serum biochemistry and liver histopathology.Itwas considered that the efficacy of Gankang Suppository may does not only result from itspotent suppression of DHBV replication,but be relation to its other active component(glycyrrchizin,lentinan).All of these above,it is indicated sufficiently that the compoundpreparation of Gankang Suppository had some advantage in treatment of hepatitis B.
建立一套检测乙型肝炎病毒基因的Taqman探针实时荧光定量PCR系统、分别利用HepG2．2．15细胞模型和鸭乙型肝炎模型于体外、体内研究乙型肝炎病毒，从而建立并完善抗乙型肝炎病毒药物筛选、评价体系。并利用该体系评价肝康栓体内、外抗乙型肝炎病毒的作用。
【方法】
1．根据病毒基因组和核苷酸序列特点，分别设计3对特异性引物及Taqman探针。利用这3对引物分别扩增HBV DNA、DHBV DNA及DHBV cccDNA目的基因片段。PCR产物纯化、回收后，克隆入pUCm-T载体，转化DH5α菌株，筛选阳性菌落，提取重组质粒。重组质粒经PCR及测序鉴定后，用于制备实时荧光定量PCR的标准品和绘制标准曲线。通过优化反应体系和循环参数，建立乙型肝炎病毒基因Taqman探针实时荧光定量PCR检测系统。并进一步评价该系统的灵敏度、特异度及可重复性。
2．体外培养HepG2．2．15细胞，观察该细胞培养1、2、4、6、8、10、12、14天时的生长情况和HBsAg、HBeAg的分泌情况。用MTT法检测肝康栓和拉米夫定对HepG2．2．1 5细胞的细胞毒性作用，计算肝康栓和拉米夫定的半数中毒浓度。并分别用ELISA法或PCR法检测肝康栓(12mg／ml、10mg／ml、6mg／ml和5mg／ml的终浓度)与拉米夫定(0．2μg／ml、1μg／ml、5μg／ml和25μg／ml的终浓度)作用4、7、10天时，HepG2．2．15细胞培养上清液中HBsAg、HBeAg、HBV DNA的抑制作用。计算培养第10天时肝康栓和拉米夫定抑制HepG2．2．15细胞上清液中HBsAg、HBeAg分泌及HBV DNA复制的半数有效浓度。最后评价肝康栓的选择指数。
3．分别提取244份武汉地区成年樱桃谷鸭血清中的DHBV DNA，并进行PCR扩增和琼脂糖凝胶电泳。估计武汉地区成年樱桃谷鸭DHBV携带率。取1日龄樱桃谷雏鸭96只，利用PCR法筛选先天DHBV DNA(-)雏鸭用于制备动物模型，并估计樱桃谷雏鸭DHBV自然感染率。通过胫静脉注射DHBVDNA强阳性血清(0．2ml／只)，利用先天DHBV DNA(-)雏鸭制备后天感染鸭乙型肝炎病毒动物模型，并计算DHBV造模感染率。
4．采用正常樱桃谷雏鸭研究肝康栓短期毒性反应。将后天感染鸭乙型肝炎病毒动物模型雏鸭随机分为：模型对照组，ACV对照组，大、中、小剂量肝康栓治疗组，每组12只；再取12只2周龄的正常雏鸭作为正常对照组。分别于第一次给药前(T_0)、给药14d(T_(14))、给药28d(T_(28))和停药7d(P_7)时，胫静脉取血(0．5ml／只)，分离血清，检测肝康栓对雏鸭血清中DHBVDNA的抑制情况和血清ALT、AST的影响。并于停药7d时将各组鸭处死，统一取肝右叶2块组织，分别用于检测肝脏DHBV DNA、DHBVcccDNA和组织病理学。
【结果】
1．本实验成功构建了pUCm-HBV DNA、pUCm-DHBV DNA和pUCm-DHBVcccDNA三种质粒标准品。在(1×10~2～1×10~9)copies／ml浓度范围内，三种标准品的含量与Ct值的相关系数r分别为-1．00、-0．999和-0．997。(5×10~3～5×10~8)copies／ml 6个浓度的三种质粒标准品，在同一实时荧光定量PCR仪上重复进行4次扩增，Ct值的变异系数均小于5％。利用本实验所建立的Taqman探针实时荧光定量PCR系统检测HBV DNA、DHBV DNA和DHBV cccDNA的灵敏度分别为：5×10~1 copies／ml、5×10~1 copies／ml和1×10~2copies／ml；并且HBV DNA阳性上清液、DHBV DNA阳性鸭血清和DHBV cccDNA阳性鸭肝组织用本法检测均出现阳性扩增，而空白的培养基、正常鸭血清及正常鸭肝组织均未出现阳性扩增。
2．①HepG2．2．15细胞按1×10~6／L浓度接种、培养后，第8～12天细胞生长状态最佳；并且用ELISA法检测培养上清发现培养1天后，检测细胞上清液中的HBsAg和HBeAg均为阳性，其后培养上清液中HBsAg及HBeAg的分泌量随着培养时间的增长而逐渐增加，在培养第10天达到高峰。培养第1-6天时HBsAg分泌增长速度较HBeAg快；但是整个培养过程中，HBeAg分泌量均高于同时期HBsAg的分泌量。
②肝康栓在(7．5～60)mg／ml浓度范围内，对HepG2．2．15细胞增殖的抑制作用随肝康栓的浓度增加而增强，当肝康栓浓度小于15mg／ml时，对细胞增殖的抑制率＜20%。
③12mg／ml的肝康栓作用10天后，HBsAg、HBeAg的抑制率达最大，分别为68．2％和62．7％。呈明显的时间和剂量依赖性；而3TC在25μg／ml浓度下作用7天，HBsAg、HBeAg的抑制率最大，分别为50．1％和47．3％。且3TC培养10天时，HBsAg、HBeAg的抑制率均较培养7天时减弱。无明显的时间依赖性。
④肝康栓在12mg/ml浓度、作用10天时，对HepG2．2．15细胞上清中HBV DNA的抑制率较强，为78．8％；而3TC在25μg／ml浓度、作用10天时，对HepG2．2．15细胞上清中HBV DNA的抑制率最强，为97．9%。
⑤肝康栓和3TC抑制HBV DNA的选择指数分别为6．14和31450．5。
3．在244份武汉地区采集的成年樱桃谷鸭血清标本中，52份为DHBV DNA阳性血清，估计武汉地区成年樱桃谷鸭DHBV携带率为：[16．64％～26．87%](95％置信区间)。而96只1日龄樱桃谷雏鸭中，在接种前检测DHBV DNA，只有11只为DHBV DNA阳性，估计樱桃谷雏鸭DHBV自然感染率为[6．52％～19．36%](95％置信区间)。随机选取1日龄DHBV DNA(-)的樱桃谷雏鸭80只，接种DHBV DNA强阳性血清1周后，69只为DHBV DNA阳性，8只为阴性，3只死亡，DHBV造模感染率为86．25%。
4．①肝康栓大、中、小剂量组雏鸭给药前、给药7天、给药14天、给药28天时，与对照组雏鸭相比，在羽毛色泽，步态，进食状况，精神状态，对刺激的反应等方面也均无明显差异；各组雏鸭在试验各阶段，体重及体重增重值均无统计学差异(p＞0．05)。
②肝康栓大剂量组雏鸭血清DHBV DNA始终低于同期其他组，且在停药7天时下降至最低(p＜0．01)；肝康栓大、中剂量组在停药7天后DHBV DBA均未出现反弹，而肝康栓小剂量组及ACV对照组均有不同程度的反弹。
③停药7天时，肝康栓大剂量组雏鸭肝组织DHBV DNA和DHBV cccDNA均受明显抑制，结果有统计学意义(p＜0．05)。
④与同期模型组比较，肝康栓中、大剂量组雏鸭在治疗28天和停药7天时血清ALT明显降低，有显著差异(p＜0．01)。肝康栓大剂量组雏鸭在治疗14天时血清AST也明显降低，有显著差异(p＜0．05)；与同期ACV对照组比较，肝康栓大剂量组在给药28天时，血清ALT明显降低，有显著差异(p＜0．05)。停药7天时，肝康栓中、大剂量组ALT也明显降低，有显著差异(p＜0．05)。而ACV对照组在治疗过程中ALT、AST均未见显著下降。
⑤肝组织病理检查结果显示：肝康栓小、中、大剂量组与模型组相比，汇管区炎性细胞浸润和肝细胞点、灶状坏死均有不同程度的改善。其中肝康栓大、中剂量组改善较为明显。
【结论】
1．本实验成功构建了一套检测乙型肝炎病毒基因的Taqman探针实时荧光定量PCR系统，并且通过方法学评价该系统具有很好的灵敏度、特异度和可重复性。基本建立了一套较完善的抗乙型肝炎病毒药物筛选、评价体系。
2．培养第8～12天的HepG2．2．15细胞处于生长高峰期，在此期进行药物实验较适宜。肝康栓体外实验的细胞毒性较小，并且对HepG2．2．15细胞培养上清液中HBsAg、HBeAg及HBV DNA有一定的抑制作用。
3．武汉地区成年樱桃谷鸭的DHBV携带率不高，其雏鸭DHBV自然感染率较低，适用于制备感染DHBV的鸭乙型肝炎动物模型。并且在本研究中成功制备了后天感染DHBV的樱桃谷雏鸭模型。
4．肝康栓对雏鸭无明显短期毒性作用，初步提示肝康栓作为治疗慢性乙型肝炎的药物是安全的。肝康栓能抑制模型雏鸭血清中的DHBV DNA，且存在一定的剂量和时间依赖性。肝康栓能有效抑制模型雏鸭肝组织中的DHBV DNA和DHBV cccDNA。肝康栓还能改善雏鸭的血清生化学和肝组织病理学。我们认为这些作用除了与肝康栓能有效抑制DHBV DNA的复制外，还与其组方中的有效成分(甘草甜素、香菇菌多糖)有关。这也充分显示了肝康栓作为复方制剂治疗慢性乙型肝炎的优势。
【Objective】
To establish a real-time fluorescent quantitation PCR system using Taqman probe fordetecting hepatitis B virus gene.The HepG2.2.15 cell strain and duck hepatitis B animalmodel were used to study hepatitis B virus respectively in vitro or in vitro.Accordingly,thescreening-evaluation system for anti-hepatitis B virus drugs was established.The effect ofGankang Suppository on hepatitis B virus in vitro and in vivo was studied utilizing thissystem.
【Methods】
1.According to the characters of viral genome and nucleotide sequence,3 special primerpairs and Taqman probe were designed.The target gene fragments of HBV DNA、DHBVDNA and DHBV cccDNA were amplified and were cloned in pUCm-T vector after PCRproducts purification and gel extraction,and the plasmids were transformed into DH5αstrains.The recombinant plasmids evaluated by PCR and sequencing were prepared for standardsubstance and standard curve of real-time quantitation PCR.Optimizing the reaction systemand parameter,the real-time fluorescent quantitation PCR system using Taqman probe fordetecting hepatitis B virus gene was established.The sensibility,specificity and repeatabilityof this system were estimated.
2.The growth status and HBsAg、HBeAg secretion of HepG2.2.15 were observed afterculturing 1、2、4、6、8、10、12、14d.The cytotoxic effect of Gankang Suppository and lamivudine were detected by MTT assay,and the 50% Toxic Concentrations wereaccounted.The HBsAg、HBeAg、HBV DNA in supernate were detected by ELISA and PCRon 4~(th)、7~(th)、10~(th)day after adding Gankang Suppository (12mg/ml、10mg/ml、6mg/ml and5mg/ml)and lamivudine (0.2μg/ml、1μg/ml、5μg/ml and 25μg/ml).The 50% EffectiveConcentration and Selection Index of Gankang Suppository and lamivudine to HBsAg、HBeAg、HBV DNA in supernate on 10~(th)day were accounted.
3.The DHBV DNA extracted from 244 serum of adult Yingtao Gu duck in Wuhan wasdetected by PCR and agarose gel electrophoresis and the DHBV DNA positive rate wasestimated.The congenital DHBV DNA(-)ducklings picked from 96 Yingtao Gu ducklingsby PCR were used to prepared animal model and the DHBV natural infection rate of YingtaoGu ducklings was also estimated.The method of DHBV DNA positive serum injection(0.2ml)via vena cruralis was used to prepare postnatal infection duck hepatitis B virus animal model,and the DHBV infection rate was accouted.
4.The normal Yingtao Gu ducklings were used to study short term toxicity effect ofGankang Suppository.The ducklings of postnatal infectious duck hepatitis B virus weredivided randomly to:control group,ACV control group,Gankang Suppository large-dosegroup、medium-dose group、small-dose group,(12 ducklings in every group),and 12 twoweeks old normal ducklings were selected for normal control group.The DHBV DNA,ALTand AST were respectively detected before treatment (T_0),14 days (T_(14))and 28 days (T_(28))after treatment,and 7 days after withdrawal (P_7).The histopathological change,DHBV DNA,and DHBV cccDNA of liver tissue was observed 7 days after withdrawal.
【Results】
1.The three standard substances of pUCm-HBV DNA、pUCm-DHBV DNA andpUCm-DHBV cccDNA were successfully constructed.In the range of (1×10~2～1×10~9)copies/ml,the coefficient correlation (r)of these standard substances content to Ct were:-1.00,-0.999 and-0.997 respective.In the range of (5×10~3～5×10~8)copies/ml,the Ct coefficient of variability of these standard substances were all less than 5%,which weredetected repetitively for 4 times in the same instrument for real-time PCR.The sensibilities ofdetecting HBV DNA,DHBV DNA and DHBV cccDNA used this real-time fluorescentquantitation PCR system were 5×10~1copies/ml、5×10~1copies/ml and 1×10~2copies/ml.Thepositive amplification was detected in HBV DNA positive supernate,DHBV DNA positiveduck serum and DHBV cccDNA positive hepatic tissue,conversely in blank culture media,normal duck serum and hepatic tissue.
2.①HepG2.2.15 cell growth best on 8~(th)-12~(th)day after microbiomation.The HBsAg andHBeAg in supernate were positive on 1st day,and the secretory volume of HBsAg andHBeAg increased gradually along with culture time lapsing,and achieved peak on 10~(th)day.Even though the increasing velocity of HBsAg secretory volume bigger than HBeAg in 1~(st)-6~(th),the secretory volume of HBeAg always more than HBsAg in the same period duringwhole culture.
②In the range of (7.5～60)mg/ml Gankang Suppository,the inhibitory effect toHepG2.2.15 cell multiplication enhanced gradually along with drug concentration increasing.And when the concentration of Gankang Suppository was small than 15mg/ml,the inhibitoryrate of HepG2.2.15 cell multiplication was small than 20%.
③The inhibitory rate of HBsAg and HBeAg on 10th day after adding 12mg/mlGankang Suppository were the greatest:68.2% and 62.7%.It showed apparent time and dosedependent.And the inhibitory rate of HBsAg and HBeAg on 7~(th)day after adding 25μg/ml3TC were the greatest:50.1% and 47.3%,and the inhibitory rate of HBsAg and HBeAg on10~(th)day was lower than that on 7~(th)day,and did not show time and dose dependent.
④The inhibitory rate of HBV DNA of supernate was greatest (78.8%)on 10~(th)day afteradding 12mg/ml Gankang Suppository.However,The inhibitory rate of HBV DNA ofsupernate was greatest (97.9%)on 10~(th)day after adding 25μg/ml 3TC.
⑤The selection index of Gankang Suppository and 3TC were 6.14 and 31450.5.
3.There were 52 DHBV DNA positive sera in 244 sera of adult Yingtao Gu duck collected in Wuhan,and the DHBV DNA positive rate in adult Yingtao Gu duck was[16.64%～26.87%] (95% confidence intervals).There were only 11 DHBV DNA positiveducklings in 96 one day old Yingtao Gu ducklings,detected before injecting DHBV DNAserum.The DHBV DNA natural infection rate of Yingtao Gu ducklings was [6.52%～19.36%] (95% confidence intervals).In 80 one day old Yingtao Gu ducklings randomselected to prepare model,69 ducklings were DHBV DNA positive after 1 week of injectingDHBV DNA positive serum.The DHBV infectious rate was 86.25%.
4.①Before treatment,7 days,14 days and 28 days after treatment,no significantdifferences were found among the Gankang Suppository large-dose group、medium-dosegroup、small-dose group and control group,in terms of feather color/luster,gait,food-taking,mental status and response to stimuli,and no significant differences were found among everygroups in every experimental stages,in terms of body weight and weight gain.(P＞0.05)
②The DHBV DNA level in Gankang Suppository large-dose group was always lowerthan other groups in the same stage,and it descended to the minimum on P_7 (P＜0.01).TheDHBV DNA level in Gankang Suppository large-dose group and medium-dose group had notrebounded on P_7,however,the DHBV DNA level in Gankang Suppository small-dose groupdid not rebound had rebounded.
③The DHBV DNA and DHBV cccDNA of hepatic tissue in the Gankang Suppositorylarge-dose group had significantly decreased on P_7(P＜0.05).
④Compared with model control group,the ALT values of Gankang Suppositorylarge-dose group、medium-dose group were significantly lower on T_(28)and P_7 (P＜0.01),andthe AST value in Gankang Suppository large-dose group was also significantly lower on T_(14)(P＜0.05).Compared with ACV group,the ALT level of Gankang Suppository large-dosegroup had significantly decreased at T_(28)(P＜0.05),and the ALT level of Gankang Suppositorylarge-dose group,medium-dose group had significantly decreased at P_7(P＜0.05).However,the ALT and AST level of ACV control group had not significantly decreased during thewhole treatment.
⑤Histopathological examination of the liver showed:Compared with DHBV modelcontrol group,the inflammatory cell infiltrate and necrosis in Gankang Suppositorylarge-dose group,medium-dose group and small-dose group were all alleviated,especially inlarge-dose group and medium-dose group.
【Conclusion】
1.In the study,a real-time fluorescent quantitation PCR system using Taqman probe fordetecting hepatitis B virus gene was successfully established,and sensibility,specificity andrepeatability of this system were very well estimated by methodology.A screening-evaluationsystem for anti-hepatitis B virus drugs was established in principle.
2.The drug study was condign to carry out on 8~(th)-10~(th)of HepG2.2.15 cell culture,inwhich phase the cell was in summit of growth.The cytotoxicity of Gankang Suppository wasslight in vitro,and it can inhibit the secretion of HBsAg、HBeAg and HBV DNA certainly.
3.The Yingtao Gu duckling was applied to prepare duck hepatitis B animal model byDHBV injection,because the DHBV infection rate in Yingtao Gu duck in Wuhan and theDHBV natural infection rate in the duckling were both low.The Yingtao Gu ducklinghepatitis B model infected postnatal DHBV was successfully prepared.
4.Gankang Suppository had no obvious short-term toxicity to ducklings,it prompted thatGankang Suppository is safe for treating hepatitis B.It was dose and time dependent thatGankang Suppository inhibited the DHBV DNA level in model ducklings.GankangSuppository could effectively suppress the DHBV DNA and DHBV cccDNA in hepatic tissue.Gankang Suppository could also improve the serum biochemistry and liver histopathology.Itwas considered that the efficacy of Gankang Suppository may does not only result from itspotent suppression of DHBV replication,but be relation to its other active component(glycyrrchizin,lentinan).All of these above,it is indicated sufficiently that the compoundpreparation of Gankang Suppository had some advantage in treatment of hepatitis B.
引文
1 姜军平．实用PCR基因诊断技术．北京：世界图书出版公司，1996．75-76．
2 Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic Type Bhepatitis: a prospective study[J]. Hepatology, 1988,8(3):493-496.
3 Nassal M. Novel molecular approaches toward therapy of chronic hepatitis B[J]. Arch Virol, 1997,142(3):611-628.
4 Suzuki F, Tsubota A, Akuta N, et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy[J]. J Gastroenterol, 2002,37(11):922-927.
5 中华医学会肝病学分会．慢性乙型肝炎防治指南．中华传染病杂志2005．421-429．
6 Garcia-Meijide M, Eddington N, Brill J, et al. Multi-center evaluation of the second-generation Digene hybrid capture Ⅱ HBV test. Hepatology, 1998,28(4 Pt 2):579A.
7 Garcia-Meijide M, Brill J, Eddington N, et al. Performance characteristics of the Digene hybrid capture Ⅱ hepatitis B DNA test. Hepatology, 1998,28(4 Pt 2):486A.
8 Bi(?)che I, Nogu(?)s C, Paradis V, et al. Quantitation ofhTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res,2000 Feb. 452-459.
9 Miley W J, Suryanarayana K, Manns A, et al. Real-time polymerase chain reaction assay for cell-associated HTLV type I DNA viral load. AIDS Res Hum Retroviruses, 2000 May, 16(7): 665-675.
10 Lallemand F, Desire N, Rozenbaum W, et al. Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay. J Clin Microbiol, 2000 Apr,38(4): 1404-1408.
1 黄祯祥，主编。医学病毒学基础及实验技术。北京：科学出版社，1990．143～146．
2 Derek Kinchington, Raymond F.Schinazi. Antiviral Metheods and Protocols. Humana Press Totowa, New Jersey, 2000:51.
3 Sells MA, Chen ML, Acs G. Production of hepatitisB virus Paticles in HepG2 cells transfected with cloned hepatitis B virus, DNAProc. Natl. Acad. Sci. USA, 1987,B4:1005-1009.
4 唐红，赵连三，王锦蓉。利用体外细胞培养系统筛选抗-HBV活性中草药的初步研究[J]。中华传染病杂志，1992，10(4．)：215-218．
5 徐叔云，卞如濂，陈修，主编。药理实验方法学[M]。北京：人民卫生出版社，2001：1729．
6 Sells MA, Zelent AZ, Shvartsman M, et al. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol, 1988,62(8):2836-2844.
7 Sells, M.A, Zelent, A.Z, Shvartsman, M, Acs, G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. Journal of virology, 1988,62:2836-2844.
8 Steven F. Innaimo, Maria Seifer, Gregory S, et al. Identification of BMS-200475 as a potent and selective inhibitor of Hepatitis B Virus. Antimicrob Agents Chemother, 1997,41 (7): 1444.
9 Robert W King, Stephanie K Ladner, Thomas J Miller. Inhibition of human hepatitis B virus replication by At-61,a phenylpropenamide dericative, alone and in combination with (2) b-L-29, 39-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother, 1998,42(12):3179.
10 Karl Deres, Claus H Schroder, Arnold Paessens, et al. Inhibition of hepatitis B virus replication b y drug induced depletion of nucleocappsids. Science, 2003,229:893.
11 Ramesh K. Sood, Vishweshwar S. Bhadti, Ali I. Fattom, et al. Novel ring-expanded nucleoside analogs exhibit potent and selective inhibition of hepatitis B virus replication in cultured human hepatoblastoma cells. Antivital Research, 2003,53:159.
12 Brent E Korba, Malcolm R Boyd. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother, 1996,40(5): 1282.
13 Chang CN, Skalski V, Hua Zhou H J, et al. Biochemical pharmacology of (+)and(-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem, 1992,267:22414-11420.
14 Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-l-[2-(hydroxymethyl)1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother, 1992,36:2686-2692.
15 Mosman T. Rapid colorimetric assay for cell growth and survial:Modification to the tetrazolium dye procedure giving improved sensitivity, and veliability[J]. J Immunol Methods, 1986.271.
16 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxity assays. J Immunol Methods, 1983.Dec 16,65(1-2):55-63.
17 曹鸿鹏，陶佩珍。拉米夫定等六种药物的体外抗乙型肝炎病毒作用。中华医学杂志，2001．1004-1007．
18 Garcia-Meijide M, Eddington N, Brill J, et al. Multi-center evaluation of the second-generation Digene hybrid capture Ⅱ HBV test. Hepatology, 1998, 28(4 Pt2):579A.
1 Msaon WS, Seal G, Summers J, et al. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus[J]. J Virol,1980. 829-836.
2 Lin E, Luscombe C, Colledge D, et al. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother,1998. 2132-2137.
3 Foster WK, Miller DS, Scougall CA, et al. Effect of antiviral treatment with entecavir on age- and dose- related outcomes of duck hepatitis B virus infection. J Virol, 2005,79(9):5819-5832.
4 邓学龙，朱宇同，方宏勋等。广州地区3个鸭种1日龄雏鸭垂直感染鸭乙肝病毒调查[J]。广东中医药大学学报1997，14(4)：274-275．
5 杨文刚，李壮，陈鸿珊。鸭乙型肝炎实验感染后在外周血和肝脏中的动态[J]．病毒学报，1988,4(3)：259．
6 姜军平．实用用PCR基因诊断技术．北京：世界图书出版公司，1996．75-76．
7 Deres K, Schroder CH, Paessens A ,et al. Inhibition of hepatitis B virus replication by drug-induced depletion ofnucleocapsids [J]. Science, 2003,299:893-896.
8 Hu J, Toil DO, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids [J]. EMBOJ, 1997,16:59 - 68.
9 Omata MI. DHBV and liver disease[J]. Gastroenterology, 1983,85:260.
10瞿涤，闻玉梅，林飞卿，等。七个鸭种携带鸭乙型肝炎病毒的研究[J]．中华传染病杂志，1985,4(3)：133-135．
11 Niu Jianzhang, Wang Yanyan, Qiao, et al. Effect of Phyanthus amarus on duck hepatitis B virus replication in vivo. JMed virol, 1990,32:212.
12 Cova L, Hantz O, Arliaud-Cassin M, et al. Comparative study of DHBV DNA level and endogenous DNA-p activity in naturally infected ducklings in France. J Virol Method, 1985,10:251.
13邓学龙，朱宇同，方宏勋，等。野水鸭等携带鸭乙型肝炎病毒的研究初报。海南医 学，1997，4：276．
14 Vickery K, Cossart Y. DHBV manipulation and prediction of the outcome of infection. J Hepatol, 1996,35:504-509.
15 Jilbert AK, Miller DS, et al. Kinetics of duck hepatitis B virus infection following low dose virus inoculation:one virus DNA genome is infectious in neonatal ducks. Virology, 1996,226:338-345.
16陈压西，郭树华，张定凤，等。重庆麻鸭乙型肝炎动物模型的建立及应用。中西医结合肝病杂志，1 994，4：25．
17李丹，陈紫榕。三氧化二砷和胸腺因子D抗乙型肝炎病毒的体外实验。福建医科大学学报，2003，37(3)：320．
1 邓学龙，刘妮，郭兴伯，等。鸭乙型肝炎病毒实验感染樱桃谷鸭后在肝脏和外周血中的动态[J]．广州中医药大学学报，1997，14(1):37-39．
2 中华医学会肝病学分会、感染病学分会．慢性乙型肝炎防治指南[J]．中华肝脏病杂志,2005．881-891．
3 Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis[J]. N Engl J Med, 1997,336(5):347-356.
4 Da Silva LC, Pinho JR, Sitnik R, et al. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B[J]. J Gastroenterol, 2001,36(7):476-485.
5 Honkoop P, Niesters HG, De Man RA, et al. Lamivudine resistance in immunocoompetent chronic hepatitis B.Incidence and patterns[J]. Hepatol, 1997,26(6): 1393-1395.
6 Dienstag JL, Schiff ER, Wrighe TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States[J]. N Engl J Med, 1999,341 (17):1256-1263.
7 Smis KA, Woodland AM. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection[J]. Pharmcotherapy, 2006,26( 12): 1745-1757.
8 Mohanty SR, Kupfer SS, Khiani V. Treatment of chronic hepatitis B[J]. Nat Clin Pract Gastroenterol Hepatol, 2006,3(8):446-458.
9 Delaney WE, Miller TG, Isom HC. Use of the hepatitis B virus recombinant baculovirus-Hep2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother, 1994,43(8):2017-2026.
10 Kroes B H, Beukelman CJ, Vandenberg AJ ,et al. Inhibition of human complement by β-glycyrrhetinic acid. Immunology, 1997,90:115.
11 Hiromitsu K. Long-term treatment of chronic hepatitis C with gly-cyrrhizinzin [Stronger Neo-Mimophagen C (SNMC)]for preventing liver cirrhosis and hepatocellular carcinoma. Oncology, 2002,69:94.
12 Fujisawa Y, Sakamoto M, Matsushita M, et al. Gly-cyrrhizin inhibits the lytic pathway of complement-possible mechanism of its anti - inflammatory effect on liver cells in viral hepatitis[J]. Microbiol Immunol, 2000,44(9):799-804.
13 Wood AJJ．阿昔洛韦应用于年概况．中外医院合成、生化药、制剂分册，1993，14(6)：353-357．
14蔡钦生，冯美卿，周佩，等。抗病毒前体药物的研究进展[J]。中国新药杂志，2002．838．
15杨道锋，田德英，沈汉馨。肝康栓对于慢性乙型肝炎的临床疗效。中西医结合肝病杂志，2002，12(5)：270～271．
1 Lurman A. Eine icterusepidemie. Berl Klin Wochenschr,1885.20-23.
2 Hartfall S J, Garland HG, Goldie W. Gold treatment of arthritis: A review of 900 cases. Lancet, 1937,2:784-788.
3 Flaum A, Malmros H, Persson E. Eine nosocomiale Iktarus Epidemic. Acta Med Scand, 1926,16(suppl):544-553.
4 Ministry of Health. Acute infectious jaundice and administration of measles serum. In: McNalby AS, et al. On the State of Public Health Annual Report of the Chief Medical Officer of the Ministry of Health for the Year 1937. London: HMSO, 1937:iv-235.
5 Memorandum prepared by Medical Officers of the Ministry of Health. Homologous serum jaundice. Lancet, 1943.83-88.
6 Fox JP, Manso C, Penna HA, Para M. Observations on occurrence of icterus in Brazil following vaccination against yellow fever. Am JHyg, 1942,36:63-116.
7 Sawyer WA, Meyer KF, Eaton MD, et aI. Jaundice in army personnel in the western region of the United States and its relation to vaccination against yellow fever. Am J Hyg, 1944,39:337-430.
8 Seeff LB, Beebe GW, Hoofnagle JH, et al. Aerologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl JMed, 1987,316:965-997.
9 Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma: Report of seven cases. JAMA, 1943,121 : 1332-1334.
10 Morgan HW, Williamson DAJ. Jaundice following administration of human blood products. Br Med J, 1943,1:750-753.
11 Zuckerman AJ. Post-transfusion hepatitis.In: Zuckennan AJ, et al. Human Viral Hepatitis: Hepatitis-Associated Antigen and Viruses, 2nd ed. Amsterdam North-Holland, 1975:207-223.
12 MacCallum FO. Homologous serum jaundice. Lancet, 1947,2:691-692.
13 World Health Organization. Advances in viral hepatitis. Report of the WHO Expert Committee on Viral Hepatitis. WHO Technical Report Serise 602. Geneva: WHO, 1977.
14 Murray R. Viral hepatitis. Bull NY AcadMed, 1955,31:341-358.
15 Krugman S, Giles JP, Hammond J. Infectious hepatitis: Evidence for two distinctive clinical, epidemiological and immunological types of infection. JAMA, 1967,200:365-373.
16 Krugman S, Giles JP, Hammond J. Hepatitis virus: Effect of heat on the infectivity and antigenicity of the MS- 1 and MS-2 strain. J Infect Dis, 1970,122:423-436.
17 Blumberg BS, Krugman S, Moderators. Passive and active immunization and treatment. In: Szmuness W, Alter HJ, Maynard JE, et al. Viral Hepatitis-1981 International Symposium. Philadelphia: Franklin Institute Press, 1982:377-544.
18 Blumberg BS, Gerstley BJS, Hungerford DA, et al. A serum antigen(Australia antigen) in Down's syndrome, leukemia and hepatitis. Ann Intern Med, 1967,66:924-931.
19 Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci, 1968,60:814-821.
20 Okochi K, Murakami S. Observatons on Australia antigen in Japanese. Vox Sang, 1968,15:374-385.
21 Almeida JD, Zuckerman AJ, Taylor PE, Waterson AP. Immune electron microscopyof the Australia-SH(serum hepatitis) antigen. Microbios, 1969,1 : 117-123.
22 Boyer ME, Blumberg BS, Wemer B. Particles associated with Australia antigen in the sera of hepatitis with leukemia, Down's syndrome and hepatitis. Nature, 1968,218:1057-1059.
23 Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet, 1970,1:695-698.
24 Kaplan PM, Gerin JL, Alter HJ. DNA polymerase associated with human hepatitis B antigen. J Virol, 1973,12:995-1005.
25 Robinson WS. DNA and DNA polymerase in the core of the Dane particle of hepatitis B. Am J Med Sci, 1975,270:151-159.
26 Magnius LO Espmark JA. Specificities in Australia antigen positive sera distinct from the LeBowvi er determinants. J Immunol, 1972,109:1017-1021.
27 Robinson WS, Lutwick LI. The virus of hepatitis, type B. (Second of two parts). The New England journal of medicine, 1976,295:1232-1236.
28 Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw)cloned in E.coli. Nature, 1979,281 (5733):646-650.
29 Xiong X, Flore C , Yang H , et al. Mutations in hepatitis B virus DNA polymerase associated with resistance to lamivudine do not confer resistance to Adefovir in vitro[J]. Hepatology, 1998.1669.
30 Dejean A, Sonigo P, Wain-Hobson S, Tiollais P. Specific hepatitis B virus integration in hepatocellular carcinoma DNA through a viral 11-base-pair direct repeat. Proc Natl Acad Sci USA, 1984,81 (17):5350-5354.
31 成军，刘妍，洪源等．基因表达谱芯片技术筛选乙型肝炎病毒X蛋白反式调节基因．世界华人消化杂志2003．920-924．
32 Milich DR, Chen MK, Hughes JL, et al. The secreted hepatitis B precore antigen can modulate the immune response to the uncleocap sid : a mechanism for persistence[J]. J Immunol, 1998.2013.
33 董长垣．现代分子病毒学[M]．武汉：武汉大学出版社，1995：158．
34 Bancroft WH, Mundon FK, Russell PK. Detection of additional antigenic determinants of hepatitis B antigen. J Immunol, 1972,109(4):842-848.
35 Hu J, Tof t DO, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into uncleocapsids[J]. EMBO J, 1997,16:59.
36 Bouchard MJ, Puro RJ, Wang L, et al. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify target s of the HBX protein involved in hepatitis B virus replication [J]. J Virol, 2003,77:7713.
37 Seeger C, Mason WS. Hepatitis B virus biology[J]. Microbiol Mol Biol Rev, 2000,64:51.
38 Murakamis. Hepatitis B virus X protein: st ructure, function and biology[J]. Intervirology, 1999,42:81.
39 Dienstag JL. Drug Therapy: Hepatitis B virus infection. N Engl J Med,2008 Oct 2. 1486-1500.
40 Suzuki, F, Tsubota, A, Akuta, N, et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy[J]. J Gastroenterol, 2002,37(11 ):922-927.
41 Nassal, M. Novel molecular approaehes toward therapy of chronic hepatitis B[J]. Arch Virol, 1997,142(3):611-628.
42 Liaw, Y. F, Tai D. I, Chu, C. M, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study[J]. Hepatology, 1988,8(3):493-496.
43 Malik, A. H, Lee, W. M. Chronic hepatitis B virus infection: treatment strategies for the next millennium[J]. Ann Intern Med, 2000,132(9):723-731.
44 Mahoney, F. J. Update on diagnosis, management, and prevention of hepatitis B virus infection[J]. Clin Microbiol Rev, 1999,12(2):351-366.
45 李兰娟主编．传染病学第一版．北京：人民卫生出版社，2008年6月．9-10．
46 Martinot-Peignoux, M, Boyer, N, Colombat M, Akremi, R, Pham, B.N, Ollivier, S, Castelnau, C, Valla, D, Degott, C, Marcellin, P. Serum hepatitis B virus DNA levels and liver histology in inaceive HBsAg carriers. Journal ofhepatotogy, 2002,36:543-546.
47 Rapicetta, M, Ferrari, C, Levrero, M. Viral determinants and host immune responses in the pathogenesis of HBV infection. Journal of medical virology, 2002,67:454-457.
48 Lee, W. M. Hepatitis B virus infection. The New England journal of medicine, 1997,337:1733-1745.
49 Chisari, F. V, Ferrari, C. Hepatitis B virus immunopathogenesis. Annual review of immunology, 1995,13:29-60.
50 Guidotti, L. G, Rochford, R, Chung, J, Shapiro, M, Purcell, R, Chisari, F. V. Viral clearance without destruction of infected cells during acute HBV infection. Science(New York, NY), 1999,284:825-829.
51 Webster, G. J, Reignat, S, Maini, M. K, Whalley, S. A, Ogg, G. S, King, A, Brown, D, Amlot, P. L, Williams, R, Vergani, D, Dusheiko, G. M,Bertoletti, A. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology(Baltimore, Md), 2000,32:1117-1124.
52 Dorr, R. T. Interferon-alpha in malignant and viral diseases. A review. Drugs, 1993,45:177-211.
53 于乐成，万谟彬，陈成伟．美国肝病学会慢性乙型肝炎实践指南(2007年)精要．肝脏2007．58-77．
54王竹生．慢性乙型肝炎的治疗现状与免疫疗法进展[J]．抗感染药学，2004，1(2)：56-59．
55 中华医学会肝病学分会、感染病学分会．慢性乙型肝炎防治指南[J]．中华肝脏病杂志2005，13(12)：881-891．
56李洪权，刘英，李辉．干扰素抗病毒机制及其抗病毒性肝炎中的作用[J]．中国公共卫生，2005，7(21)：890—891．
57 Melen, K, Keskinen, P, Lehtonen, A, Julkunen, I. Interferon-induced gene expression and signaling in human hepatoma cell lines. Journal ofhepatology, 2000,33:764-772.
58 Brook, M.G, MeDonald, J.A, Karayiannis, P, et al. Randomised controlled trial of interferon alfa 2A(Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: faetors that influence response[J]. Gut, 1989,30(8): 1116-1122.
59 Niederau, C, Heintges, T, Lange, S, et al. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B[J]. N Engl J Med, 1996,334(22): 1422-1427.
60 Krogsgaard, K, Bindslev, N, Christensen, E, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep)[J]. J Hepatol, 1994,21(4):646-655.
61 Simon, K, Rotter, K, Zalewska, M, et al. HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alpha-2b of patients with chronic hepatitis B[J]. Med Sci Monit, 2000,6(5):971-975.
62 Ganem, D, Prince, A. M. Hepatitis B virus infection-natural history and clinical consequences. The New England journal of medicine, 2004,350:1118-1129.
63 Chung, D. R, Yang, W. S, Kim, S. B, Yu, E, Chung, Y. H, Park, J. S. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon.American journal of nephrology, 1997,17:112-117.
64 Heathcote, J. Treatment of HBe antigen-positive chronic hepatitis B. Seminars in liver disease, 2003,23:69-80.
65 Hart, G. J, Orr, D. C, Penn, C. R, Figueiredo, H. T, Gray, N. M, Boehme, R. E, Cameron,J. M. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha,beta, and gamma. Antimicrobial agents and chemotherapy, 1992,36:1688-1694.
66 Prescott, L. M. Lamivudine useful against hepatitis B-HIV co-infection. Journal of the International Association of Physicians in AIDS Care, 1995,1:34.
67 Coates, J. A, Cammack, N, Jenkinson, H. J, Jowett, A. J, Jowett, M. I, Pearson, B. A,Penn, C. R, Rouse, P. L, Viner, K. C, Cameron, J. M. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrobial agents and chemotherapy, 1992,36:733-739.
68 Colacino, J. M, Staschke, K. A. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Progress in drug research Fortschritte der Arzneimittelforschung, 1998,50:259-322.
69 Doong, S. L, Tsai, C. H, Schinazi, R. F, Liotta, D. C, Cheng, Y. C. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proceedings of the National Academy of Sciences of the United States of America, 1991,88:8495-8499.
70 Ozgenc, F, Arikan, C, Sertoz, r. y, Nart, D, Aydogdu, S, Yagci, R. V. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antiviral therapy,2004,9:729-732.___________________________________________________________
71 Schmilovitz-Weiss, H, Melzer, E, Tur-Kaspa, R, Ben-Ari, Z. Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. Journal of clinical gastroenterology, 2003,37:64-67.
72 Allen, M. I, Deslauriers, M, Andrews, C. W, Tipples, G. A, Walters, K. A, Tyrrell, D. L,Brown, N, Condreay, L. D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.Hepatology(Baltimore, Md), 1998,27:1670-1677.
73 Ling, R, Mutimer, D, Ahmed, M, Boxall, E. H, Elias, E, Dusheiko, G. M, Harrison, T. J.Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology(Baltimore, Md), 1996,24:711-713.
74 Perrillo, R, Harm, H. W, Mutimer, D, Willems, Leung, N, Lee, W. M, Moorat, A,Gardner, S, Woessner, M, Bourne, E, Brosgart, C. L, Sshiff, E. Adefovir dipivoxil addedto ongoing lamicudine in chronic hepatitis B with YMDD mutant hepatitis B virus.Gastroenterology, 2004,126:81-90.
75 Tong, M. J, Tu, S. S. Treatment of patients with chronic hepatitis B with adefovir dipivoxil. Seminars in liver disease, 2004,24:37-44.
76 Dandri, M, Burda, M. R, Zuckerman, D. M, Wursthorn, K, Matschl, U, Pollok, J. M,Rogiers, X, CJocht, A, Kock, J, Blum, H. E, von Weizsacker, F, Petersen, J. Chronic infection with hepatitis B virus and antiviral drug evaluation in uPA mice after liver replication with tupaia hepatocytes. Journal of hepatology, 2005,42:54-60.
77 Rivkna, A, Rybalov, S. Chronic hepatitis B: current and future treatment options[J].Pharmacotherapy,2002,22(6):721-737.
78 Sureau, C, J.L.Romet-Lemonne, J.I.Mullins, M.Essex. Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA.Cell,1986.37-47.
79 Sells, M. A, M. L. Chen, G. Acs. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA,1987,84:1005-1009.
80 Sells, M.A, Zelent, A.Z, Shvartsman, M, Acs, G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. Journal of virology , 1988,62:2836-2844.
81 Nagahata, T, Kitagawa, M, Matsubara, K. Effect of oxetanocin G, a novel nucleoside analog, on DNA synthesis by hepatitis B virus virions. Antimicrobial agents and chemotherapy,1994,38:707-712.
82 Sekiya, K, Takashima, H, Ueda, N, Kamiya, N, Yuasa, S, Fujimura, Y, Ubasawa, M.2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl)esters as novel HBV-specific antiviral reagents. Journal of medicinal chemistry,2002,45:3138-3142.
83 Togashi, H, Ohno, S, Matsuo, T, Watanabe, H, Saito, T, Shinzawa, H, Takahashi, T.Interferon-gamma, tumor necrosis factor-alpha, and interleukin 1-beta supress the replication of hepatitis B virus through oxidative stress. Research communications in molecular pathology and pharmacology, 2000,107:407-417.
84 Tsurimoto T, Fujiyama A, Matsubara K. Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA. Proc Natl Acad Sci USA, 1987 Jan,84(2):444-448.
85 Yaginuma,K, Shirakata, Y, Kobayashi, M, Koike, K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci USA, 1987,84(9):2678-2682.
86 Ladner, S.K, Otto, M.J, Barker, C.S, Zaifert, K, Wang, G.H, Guo, J.T, Seeger, C, King,R.W. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrobial agents and chemotherapy, 1997,41:1715-1720.
87 King, R.W, Ladner, S.K, Miller, T.J, Zaifert, K. Perni, R.B, Conway, S.C, Otto, M.J.Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.Antimicrobial agents and chemotherapy, 1998,42:3179-3186.
88 Shi, J, Mathew, J.S, Tharnish, P.M, Rachakonda, S, Pai, S.B, Adams, M, Grier, J.P,Gallagher, K, Zhang, H, Wu, J.T, Shi, G, Geleziunas, R, Erickson-Viitanen, S, Stuyver,L, Otto, M.J, Watanabe, K.A, Schinazi, R.F. N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity.Antiviral chemistry & chemotherapy, 2003,14:81-90.
89 Ying, C, De Clercq, E, Nicholson, W, Furman, P, Neyts, J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, terofovir, L-FMAU, DAPD, penciclovir and lobucavir. Journal of viral hepatitis, 2000,7:161-165.
90 Gripon, P, Rumin, S, Urban, S, Le Seyec, J, Glaise, D, Cannie, I, Guyomard, C, Lucas, J,Trepo, C, Guguen-Guillouzo, C. Infection of a human hepatoma cell line by hepatitis B virus. Proceedings of the National Academy of Sciences of the United States of America,2002,99:15655-15660.
91 Gripon, P, Cannie, I, Urban, S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. Journal of virology,2005,79:1613-1622.
92 Blanchet, M. Sureau, C. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity. Journal of virology, 2006,80:11935-11945.
93 Rijntjes, P.J., Moshage, H.J, Yap, S.H. In vitro infection of primary cultures of cryopreserved adult human hepatocytes with hepatitis B virus. Virus research,1988,10:95-109.
94 Schulze-Bergkamen H,Untergasser A,Dax A,et al. Primary human hepatocytes-a valuable tool for investigation of apoptosis and hepatitis B virus infection[J]. J Hepatol,2003,38(6):736.
95 De Meyer S,Gong ZJ,Hertogs K,et al. Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on in vitro hepatitis B virus infection [J]. J Viral Hepat, 2000,7(2): 104.
96 Gripon, P, Diot, C, Guguen-Guillouzo, C. Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology, 1993,192:534-540.
97 Gripon, P, Diot, C, Theze, N, Fourel, I, Loreal, O, Brechot, C, Guguen-Guillouzo, C.Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. Journal of virology, 1988,62:4136-4143.
98 Ochiya, T, Tsurimoto, T, Ueda, K, Okubo, K, Shiozawa, M, Matsubara, K. An in vitro system for infection with hepatitis B virus that used primary human fetal hepatocytes.Proceedings of the National Academy of Sciences of the Unitied States of America, 1989，86：1 875-1 879．
99熊鸿燕，王思雄，胡小兵，等．鸭乙型肝炎病毒在鸭肝原代细胞中复制的实验观察．中国消毒学杂志，2001，18：203-207．
100 Seifer M,Heermann KH,Gerlich WH. Replication of hepatitis B virus in transfected nonhepatic cell [J]. Virology, 1990,179(1):300.
101 Tang H,McLachlan A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism [J]. Proc Natl Acad Sci USA, 2001,98 (4): 1841.
102 Delaney, W.E.t, Isom, H.C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant bacalovirus. Hepatology, 1998.1134-1146.
103 Delaney, W.E.t, Miller, T.G, Isom, H.C. Use of the hepatitis B virus recombinant baculcovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrobial agents and chemotherapy, 1999,43:2017-2026.
104 Ronni, T, Sareneva, T, Pirhonen, J, Julkunen, I. Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J Immunol, 1995,154:2764-2774.
105 Abdelhamed, A.M, Kelley, C.M, Miller, T.G, Furman, P.A, Isom, H.C. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. Journal of virology, 2002,76:8148-8160.
106 Sprinzl, M.F, Oberwinkler, H, Schaller, H, et al. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. Journal virology,2001.5108-5118.
107 Ren, S, Nassal, M. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genoma transduction with replication-defective adenovirus vectors. Journal of virology, 2001,75:1104-1116.
108 Gagneux P, M uchmore EA. The chimpanzee model: contributions and considerations for studies of hepatitis B virus [J]. Methods Mol Med,2004. 289-318.
109 Barker L F, Maynard J E, Purcell R H, et al. Hepatitis B Virus Infection in chimpanzees: titration of subtypes [J]. J Infect Dis, 1975,132(4):451- 458.
110 Bertoni R, Sette A, Sidney J, et al. Human class I supertypes and CTL repertoires extend to chimpanzees[J]. Immunology, 1998,161(8):4447.
111 Ogata N, Cote PJ, Zanetti AR, et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus[J]. Hepatology, 1999,30(3):779.
112 Wieland SF, Spangenberg HC, Thimme R, et al. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees[J]. Proc Natl Acad Sci USA,2004,101(7):2129.
113 Yan, R Q.Su, J J.Huang, D R.et al. Human hepatitis B virusand hepatocellular carcinoma I. Experimental infection of treeshrews with hepatitis B virus [J]. J cancer Res Clin Oncd,1996,122(5):283-288.
114 Zuckerman, A J.Scalise, G.M azaheri, M R.et al. Transmission of hepatitis B to the rhesus monkey [J]. Dev Biol Stand, 1975,30:236-239.
115 Scalise, G.M azaheri, M R.Kremastinou, J.et al. Transmission of hepatitis B to the rhesus monkey.Studies on the humoral and cell midiated immune response [J]. J M ed Primotal, 1978,7(2):114-118.
116 Mason WS , Aldrich C , Summers J ,et al. Asymmetric replication of duck hepatitis B virus DNA in liver cells : Free minus-strand DNA. Proc Natl Acad Sci USA, 1982,79(13):3997-4001.
117 Kock J , Schlicht HJ. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol, 1993,67 (8):4867-4874.
118 Breiner KM , Urban S , Glass B ,et al. Envelope protein mediated down regulation of hepatitis B virus receptor in infected hepatocytes. J Virol, 2001,75(1): 143-150.
119 Urban S. Binding of duck carboxypeptidase D to duck hepatitis B virus. Methods Mol Med, 2004,95:199-212.
120 TennantBC, Gerin JL. The woodchuck model of hepatitis B virus infection[J]. ILAR J,2001,42(2):89-102.
121 Chisari, F V. Pinkert, C A. M ilich, D R. et al. A transgenic mouse modelofthe chronic hepatitis B surface antigen carrierstate [J]. Science, 1985,230(4730): 1157-1160.
122 Kobayashi, M, Koike, K. Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene, 1984,30:227-232.
123 Guidotti L G,Matzke B ,Schaller H, et al. High level hepatitis B virus replication in transgenic mice. J Virol, 1995,69:6158-6161.
124 Wang Y,Cui F,Lv Y,et al. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice [J]. Hepatology, 2004,39(2):2318.
125 Liu F, Song Y, Liu D, et al. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA[J]. Gene Therapy, 1999,6(7): 1258.
126 Ketzinel-Gilad M, Zauberman A, Nussbaum O, et al. The use of hydrodynamic HBV animal model to study HBV biology and antiviral therapy[J]. Hepatol Res, 2006,34:228.
127 Wu, CH.Ouyang, EC.Walton, C.et al. Liver cell transplantation-novel animal model for human hepatic viral infections[J]. Croat Med J, 2001,42(4):446-450.
2 Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic Type Bhepatitis: a prospective study[J]. Hepatology, 1988,8(3):493-496.
3 Nassal M. Novel molecular approaches toward therapy of chronic hepatitis B[J]. Arch Virol, 1997,142(3):611-628.
4 Suzuki F, Tsubota A, Akuta N, et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy[J]. J Gastroenterol, 2002,37(11):922-927.
5 中华医学会肝病学分会．慢性乙型肝炎防治指南．中华传染病杂志2005．421-429．
6 Garcia-Meijide M, Eddington N, Brill J, et al. Multi-center evaluation of the second-generation Digene hybrid capture Ⅱ HBV test. Hepatology, 1998,28(4 Pt 2):579A.
7 Garcia-Meijide M, Brill J, Eddington N, et al. Performance characteristics of the Digene hybrid capture Ⅱ hepatitis B DNA test. Hepatology, 1998,28(4 Pt 2):486A.
8 Bi(?)che I, Nogu(?)s C, Paradis V, et al. Quantitation ofhTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res,2000 Feb. 452-459.
9 Miley W J, Suryanarayana K, Manns A, et al. Real-time polymerase chain reaction assay for cell-associated HTLV type I DNA viral load. AIDS Res Hum Retroviruses, 2000 May, 16(7): 665-675.
10 Lallemand F, Desire N, Rozenbaum W, et al. Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay. J Clin Microbiol, 2000 Apr,38(4): 1404-1408.
1 黄祯祥，主编。医学病毒学基础及实验技术。北京：科学出版社，1990．143～146．
2 Derek Kinchington, Raymond F.Schinazi. Antiviral Metheods and Protocols. Humana Press Totowa, New Jersey, 2000:51.
3 Sells MA, Chen ML, Acs G. Production of hepatitisB virus Paticles in HepG2 cells transfected with cloned hepatitis B virus, DNAProc. Natl. Acad. Sci. USA, 1987,B4:1005-1009.
4 唐红，赵连三，王锦蓉。利用体外细胞培养系统筛选抗-HBV活性中草药的初步研究[J]。中华传染病杂志，1992，10(4．)：215-218．
5 徐叔云，卞如濂，陈修，主编。药理实验方法学[M]。北京：人民卫生出版社，2001：1729．
6 Sells MA, Zelent AZ, Shvartsman M, et al. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol, 1988,62(8):2836-2844.
7 Sells, M.A, Zelent, A.Z, Shvartsman, M, Acs, G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. Journal of virology, 1988,62:2836-2844.
8 Steven F. Innaimo, Maria Seifer, Gregory S, et al. Identification of BMS-200475 as a potent and selective inhibitor of Hepatitis B Virus. Antimicrob Agents Chemother, 1997,41 (7): 1444.
9 Robert W King, Stephanie K Ladner, Thomas J Miller. Inhibition of human hepatitis B virus replication by At-61,a phenylpropenamide dericative, alone and in combination with (2) b-L-29, 39-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother, 1998,42(12):3179.
10 Karl Deres, Claus H Schroder, Arnold Paessens, et al. Inhibition of hepatitis B virus replication b y drug induced depletion of nucleocappsids. Science, 2003,229:893.
11 Ramesh K. Sood, Vishweshwar S. Bhadti, Ali I. Fattom, et al. Novel ring-expanded nucleoside analogs exhibit potent and selective inhibition of hepatitis B virus replication in cultured human hepatoblastoma cells. Antivital Research, 2003,53:159.
12 Brent E Korba, Malcolm R Boyd. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother, 1996,40(5): 1282.
13 Chang CN, Skalski V, Hua Zhou H J, et al. Biochemical pharmacology of (+)and(-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem, 1992,267:22414-11420.
14 Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-l-[2-(hydroxymethyl)1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother, 1992,36:2686-2692.
15 Mosman T. Rapid colorimetric assay for cell growth and survial:Modification to the tetrazolium dye procedure giving improved sensitivity, and veliability[J]. J Immunol Methods, 1986.271.
16 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxity assays. J Immunol Methods, 1983.Dec 16,65(1-2):55-63.
17 曹鸿鹏，陶佩珍。拉米夫定等六种药物的体外抗乙型肝炎病毒作用。中华医学杂志，2001．1004-1007．
18 Garcia-Meijide M, Eddington N, Brill J, et al. Multi-center evaluation of the second-generation Digene hybrid capture Ⅱ HBV test. Hepatology, 1998, 28(4 Pt2):579A.
1 Msaon WS, Seal G, Summers J, et al. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus[J]. J Virol,1980. 829-836.
2 Lin E, Luscombe C, Colledge D, et al. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother,1998. 2132-2137.
3 Foster WK, Miller DS, Scougall CA, et al. Effect of antiviral treatment with entecavir on age- and dose- related outcomes of duck hepatitis B virus infection. J Virol, 2005,79(9):5819-5832.
4 邓学龙，朱宇同，方宏勋等。广州地区3个鸭种1日龄雏鸭垂直感染鸭乙肝病毒调查[J]。广东中医药大学学报1997，14(4)：274-275．
5 杨文刚，李壮，陈鸿珊。鸭乙型肝炎实验感染后在外周血和肝脏中的动态[J]．病毒学报，1988,4(3)：259．
6 姜军平．实用用PCR基因诊断技术．北京：世界图书出版公司，1996．75-76．
7 Deres K, Schroder CH, Paessens A ,et al. Inhibition of hepatitis B virus replication by drug-induced depletion ofnucleocapsids [J]. Science, 2003,299:893-896.
8 Hu J, Toil DO, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids [J]. EMBOJ, 1997,16:59 - 68.
9 Omata MI. DHBV and liver disease[J]. Gastroenterology, 1983,85:260.
10瞿涤，闻玉梅，林飞卿，等。七个鸭种携带鸭乙型肝炎病毒的研究[J]．中华传染病杂志，1985,4(3)：133-135．
11 Niu Jianzhang, Wang Yanyan, Qiao, et al. Effect of Phyanthus amarus on duck hepatitis B virus replication in vivo. JMed virol, 1990,32:212.
12 Cova L, Hantz O, Arliaud-Cassin M, et al. Comparative study of DHBV DNA level and endogenous DNA-p activity in naturally infected ducklings in France. J Virol Method, 1985,10:251.
13邓学龙，朱宇同，方宏勋，等。野水鸭等携带鸭乙型肝炎病毒的研究初报。海南医 学，1997，4：276．
14 Vickery K, Cossart Y. DHBV manipulation and prediction of the outcome of infection. J Hepatol, 1996,35:504-509.
15 Jilbert AK, Miller DS, et al. Kinetics of duck hepatitis B virus infection following low dose virus inoculation:one virus DNA genome is infectious in neonatal ducks. Virology, 1996,226:338-345.
16陈压西，郭树华，张定凤，等。重庆麻鸭乙型肝炎动物模型的建立及应用。中西医结合肝病杂志，1 994，4：25．
17李丹，陈紫榕。三氧化二砷和胸腺因子D抗乙型肝炎病毒的体外实验。福建医科大学学报，2003，37(3)：320．
1 邓学龙，刘妮，郭兴伯，等。鸭乙型肝炎病毒实验感染樱桃谷鸭后在肝脏和外周血中的动态[J]．广州中医药大学学报，1997，14(1):37-39．
2 中华医学会肝病学分会、感染病学分会．慢性乙型肝炎防治指南[J]．中华肝脏病杂志,2005．881-891．
3 Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis[J]. N Engl J Med, 1997,336(5):347-356.
4 Da Silva LC, Pinho JR, Sitnik R, et al. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B[J]. J Gastroenterol, 2001,36(7):476-485.
5 Honkoop P, Niesters HG, De Man RA, et al. Lamivudine resistance in immunocoompetent chronic hepatitis B.Incidence and patterns[J]. Hepatol, 1997,26(6): 1393-1395.
6 Dienstag JL, Schiff ER, Wrighe TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States[J]. N Engl J Med, 1999,341 (17):1256-1263.
7 Smis KA, Woodland AM. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection[J]. Pharmcotherapy, 2006,26( 12): 1745-1757.
8 Mohanty SR, Kupfer SS, Khiani V. Treatment of chronic hepatitis B[J]. Nat Clin Pract Gastroenterol Hepatol, 2006,3(8):446-458.
9 Delaney WE, Miller TG, Isom HC. Use of the hepatitis B virus recombinant baculovirus-Hep2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother, 1994,43(8):2017-2026.
10 Kroes B H, Beukelman CJ, Vandenberg AJ ,et al. Inhibition of human complement by β-glycyrrhetinic acid. Immunology, 1997,90:115.
11 Hiromitsu K. Long-term treatment of chronic hepatitis C with gly-cyrrhizinzin [Stronger Neo-Mimophagen C (SNMC)]for preventing liver cirrhosis and hepatocellular carcinoma. Oncology, 2002,69:94.
12 Fujisawa Y, Sakamoto M, Matsushita M, et al. Gly-cyrrhizin inhibits the lytic pathway of complement-possible mechanism of its anti - inflammatory effect on liver cells in viral hepatitis[J]. Microbiol Immunol, 2000,44(9):799-804.
13 Wood AJJ．阿昔洛韦应用于年概况．中外医院合成、生化药、制剂分册，1993，14(6)：353-357．
14蔡钦生，冯美卿，周佩，等。抗病毒前体药物的研究进展[J]。中国新药杂志，2002．838．
15杨道锋，田德英，沈汉馨。肝康栓对于慢性乙型肝炎的临床疗效。中西医结合肝病杂志，2002，12(5)：270～271．
1 Lurman A. Eine icterusepidemie. Berl Klin Wochenschr,1885.20-23.
2 Hartfall S J, Garland HG, Goldie W. Gold treatment of arthritis: A review of 900 cases. Lancet, 1937,2:784-788.
3 Flaum A, Malmros H, Persson E. Eine nosocomiale Iktarus Epidemic. Acta Med Scand, 1926,16(suppl):544-553.
4 Ministry of Health. Acute infectious jaundice and administration of measles serum. In: McNalby AS, et al. On the State of Public Health Annual Report of the Chief Medical Officer of the Ministry of Health for the Year 1937. London: HMSO, 1937:iv-235.
5 Memorandum prepared by Medical Officers of the Ministry of Health. Homologous serum jaundice. Lancet, 1943.83-88.
6 Fox JP, Manso C, Penna HA, Para M. Observations on occurrence of icterus in Brazil following vaccination against yellow fever. Am JHyg, 1942,36:63-116.
7 Sawyer WA, Meyer KF, Eaton MD, et aI. Jaundice in army personnel in the western region of the United States and its relation to vaccination against yellow fever. Am J Hyg, 1944,39:337-430.
8 Seeff LB, Beebe GW, Hoofnagle JH, et al. Aerologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl JMed, 1987,316:965-997.
9 Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma: Report of seven cases. JAMA, 1943,121 : 1332-1334.
10 Morgan HW, Williamson DAJ. Jaundice following administration of human blood products. Br Med J, 1943,1:750-753.
11 Zuckerman AJ. Post-transfusion hepatitis.In: Zuckennan AJ, et al. Human Viral Hepatitis: Hepatitis-Associated Antigen and Viruses, 2nd ed. Amsterdam North-Holland, 1975:207-223.
12 MacCallum FO. Homologous serum jaundice. Lancet, 1947,2:691-692.
13 World Health Organization. Advances in viral hepatitis. Report of the WHO Expert Committee on Viral Hepatitis. WHO Technical Report Serise 602. Geneva: WHO, 1977.
14 Murray R. Viral hepatitis. Bull NY AcadMed, 1955,31:341-358.
15 Krugman S, Giles JP, Hammond J. Infectious hepatitis: Evidence for two distinctive clinical, epidemiological and immunological types of infection. JAMA, 1967,200:365-373.
16 Krugman S, Giles JP, Hammond J. Hepatitis virus: Effect of heat on the infectivity and antigenicity of the MS- 1 and MS-2 strain. J Infect Dis, 1970,122:423-436.
17 Blumberg BS, Krugman S, Moderators. Passive and active immunization and treatment. In: Szmuness W, Alter HJ, Maynard JE, et al. Viral Hepatitis-1981 International Symposium. Philadelphia: Franklin Institute Press, 1982:377-544.
18 Blumberg BS, Gerstley BJS, Hungerford DA, et al. A serum antigen(Australia antigen) in Down's syndrome, leukemia and hepatitis. Ann Intern Med, 1967,66:924-931.
19 Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci, 1968,60:814-821.
20 Okochi K, Murakami S. Observatons on Australia antigen in Japanese. Vox Sang, 1968,15:374-385.
21 Almeida JD, Zuckerman AJ, Taylor PE, Waterson AP. Immune electron microscopyof the Australia-SH(serum hepatitis) antigen. Microbios, 1969,1 : 117-123.
22 Boyer ME, Blumberg BS, Wemer B. Particles associated with Australia antigen in the sera of hepatitis with leukemia, Down's syndrome and hepatitis. Nature, 1968,218:1057-1059.
23 Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet, 1970,1:695-698.
24 Kaplan PM, Gerin JL, Alter HJ. DNA polymerase associated with human hepatitis B antigen. J Virol, 1973,12:995-1005.
25 Robinson WS. DNA and DNA polymerase in the core of the Dane particle of hepatitis B. Am J Med Sci, 1975,270:151-159.
26 Magnius LO Espmark JA. Specificities in Australia antigen positive sera distinct from the LeBowvi er determinants. J Immunol, 1972,109:1017-1021.
27 Robinson WS, Lutwick LI. The virus of hepatitis, type B. (Second of two parts). The New England journal of medicine, 1976,295:1232-1236.
28 Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw)cloned in E.coli. Nature, 1979,281 (5733):646-650.
29 Xiong X, Flore C , Yang H , et al. Mutations in hepatitis B virus DNA polymerase associated with resistance to lamivudine do not confer resistance to Adefovir in vitro[J]. Hepatology, 1998.1669.
30 Dejean A, Sonigo P, Wain-Hobson S, Tiollais P. Specific hepatitis B virus integration in hepatocellular carcinoma DNA through a viral 11-base-pair direct repeat. Proc Natl Acad Sci USA, 1984,81 (17):5350-5354.
31 成军，刘妍，洪源等．基因表达谱芯片技术筛选乙型肝炎病毒X蛋白反式调节基因．世界华人消化杂志2003．920-924．
32 Milich DR, Chen MK, Hughes JL, et al. The secreted hepatitis B precore antigen can modulate the immune response to the uncleocap sid : a mechanism for persistence[J]. J Immunol, 1998.2013.
33 董长垣．现代分子病毒学[M]．武汉：武汉大学出版社，1995：158．
34 Bancroft WH, Mundon FK, Russell PK. Detection of additional antigenic determinants of hepatitis B antigen. J Immunol, 1972,109(4):842-848.
35 Hu J, Tof t DO, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into uncleocapsids[J]. EMBO J, 1997,16:59.
36 Bouchard MJ, Puro RJ, Wang L, et al. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify target s of the HBX protein involved in hepatitis B virus replication [J]. J Virol, 2003,77:7713.
37 Seeger C, Mason WS. Hepatitis B virus biology[J]. Microbiol Mol Biol Rev, 2000,64:51.
38 Murakamis. Hepatitis B virus X protein: st ructure, function and biology[J]. Intervirology, 1999,42:81.
39 Dienstag JL. Drug Therapy: Hepatitis B virus infection. N Engl J Med,2008 Oct 2. 1486-1500.
40 Suzuki, F, Tsubota, A, Akuta, N, et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy[J]. J Gastroenterol, 2002,37(11 ):922-927.
41 Nassal, M. Novel molecular approaehes toward therapy of chronic hepatitis B[J]. Arch Virol, 1997,142(3):611-628.
42 Liaw, Y. F, Tai D. I, Chu, C. M, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study[J]. Hepatology, 1988,8(3):493-496.
43 Malik, A. H, Lee, W. M. Chronic hepatitis B virus infection: treatment strategies for the next millennium[J]. Ann Intern Med, 2000,132(9):723-731.
44 Mahoney, F. J. Update on diagnosis, management, and prevention of hepatitis B virus infection[J]. Clin Microbiol Rev, 1999,12(2):351-366.
45 李兰娟主编．传染病学第一版．北京：人民卫生出版社，2008年6月．9-10．
46 Martinot-Peignoux, M, Boyer, N, Colombat M, Akremi, R, Pham, B.N, Ollivier, S, Castelnau, C, Valla, D, Degott, C, Marcellin, P. Serum hepatitis B virus DNA levels and liver histology in inaceive HBsAg carriers. Journal ofhepatotogy, 2002,36:543-546.
47 Rapicetta, M, Ferrari, C, Levrero, M. Viral determinants and host immune responses in the pathogenesis of HBV infection. Journal of medical virology, 2002,67:454-457.
48 Lee, W. M. Hepatitis B virus infection. The New England journal of medicine, 1997,337:1733-1745.
49 Chisari, F. V, Ferrari, C. Hepatitis B virus immunopathogenesis. Annual review of immunology, 1995,13:29-60.
50 Guidotti, L. G, Rochford, R, Chung, J, Shapiro, M, Purcell, R, Chisari, F. V. Viral clearance without destruction of infected cells during acute HBV infection. Science(New York, NY), 1999,284:825-829.
51 Webster, G. J, Reignat, S, Maini, M. K, Whalley, S. A, Ogg, G. S, King, A, Brown, D, Amlot, P. L, Williams, R, Vergani, D, Dusheiko, G. M,Bertoletti, A. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology(Baltimore, Md), 2000,32:1117-1124.
52 Dorr, R. T. Interferon-alpha in malignant and viral diseases. A review. Drugs, 1993,45:177-211.
53 于乐成，万谟彬，陈成伟．美国肝病学会慢性乙型肝炎实践指南(2007年)精要．肝脏2007．58-77．
54王竹生．慢性乙型肝炎的治疗现状与免疫疗法进展[J]．抗感染药学，2004，1(2)：56-59．
55 中华医学会肝病学分会、感染病学分会．慢性乙型肝炎防治指南[J]．中华肝脏病杂志2005，13(12)：881-891．
56李洪权，刘英，李辉．干扰素抗病毒机制及其抗病毒性肝炎中的作用[J]．中国公共卫生，2005，7(21)：890—891．
57 Melen, K, Keskinen, P, Lehtonen, A, Julkunen, I. Interferon-induced gene expression and signaling in human hepatoma cell lines. Journal ofhepatology, 2000,33:764-772.
58 Brook, M.G, MeDonald, J.A, Karayiannis, P, et al. Randomised controlled trial of interferon alfa 2A(Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: faetors that influence response[J]. Gut, 1989,30(8): 1116-1122.
59 Niederau, C, Heintges, T, Lange, S, et al. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B[J]. N Engl J Med, 1996,334(22): 1422-1427.
60 Krogsgaard, K, Bindslev, N, Christensen, E, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep)[J]. J Hepatol, 1994,21(4):646-655.
61 Simon, K, Rotter, K, Zalewska, M, et al. HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alpha-2b of patients with chronic hepatitis B[J]. Med Sci Monit, 2000,6(5):971-975.
62 Ganem, D, Prince, A. M. Hepatitis B virus infection-natural history and clinical consequences. The New England journal of medicine, 2004,350:1118-1129.
63 Chung, D. R, Yang, W. S, Kim, S. B, Yu, E, Chung, Y. H, Park, J. S. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon.American journal of nephrology, 1997,17:112-117.
64 Heathcote, J. Treatment of HBe antigen-positive chronic hepatitis B. Seminars in liver disease, 2003,23:69-80.
65 Hart, G. J, Orr, D. C, Penn, C. R, Figueiredo, H. T, Gray, N. M, Boehme, R. E, Cameron,J. M. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha,beta, and gamma. Antimicrobial agents and chemotherapy, 1992,36:1688-1694.
66 Prescott, L. M. Lamivudine useful against hepatitis B-HIV co-infection. Journal of the International Association of Physicians in AIDS Care, 1995,1:34.
67 Coates, J. A, Cammack, N, Jenkinson, H. J, Jowett, A. J, Jowett, M. I, Pearson, B. A,Penn, C. R, Rouse, P. L, Viner, K. C, Cameron, J. M. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrobial agents and chemotherapy, 1992,36:733-739.
68 Colacino, J. M, Staschke, K. A. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Progress in drug research Fortschritte der Arzneimittelforschung, 1998,50:259-322.
69 Doong, S. L, Tsai, C. H, Schinazi, R. F, Liotta, D. C, Cheng, Y. C. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proceedings of the National Academy of Sciences of the United States of America, 1991,88:8495-8499.
70 Ozgenc, F, Arikan, C, Sertoz, r. y, Nart, D, Aydogdu, S, Yagci, R. V. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antiviral therapy,2004,9:729-732.___________________________________________________________
71 Schmilovitz-Weiss, H, Melzer, E, Tur-Kaspa, R, Ben-Ari, Z. Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. Journal of clinical gastroenterology, 2003,37:64-67.
72 Allen, M. I, Deslauriers, M, Andrews, C. W, Tipples, G. A, Walters, K. A, Tyrrell, D. L,Brown, N, Condreay, L. D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.Hepatology(Baltimore, Md), 1998,27:1670-1677.
73 Ling, R, Mutimer, D, Ahmed, M, Boxall, E. H, Elias, E, Dusheiko, G. M, Harrison, T. J.Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology(Baltimore, Md), 1996,24:711-713.
74 Perrillo, R, Harm, H. W, Mutimer, D, Willems, Leung, N, Lee, W. M, Moorat, A,Gardner, S, Woessner, M, Bourne, E, Brosgart, C. L, Sshiff, E. Adefovir dipivoxil addedto ongoing lamicudine in chronic hepatitis B with YMDD mutant hepatitis B virus.Gastroenterology, 2004,126:81-90.
75 Tong, M. J, Tu, S. S. Treatment of patients with chronic hepatitis B with adefovir dipivoxil. Seminars in liver disease, 2004,24:37-44.
76 Dandri, M, Burda, M. R, Zuckerman, D. M, Wursthorn, K, Matschl, U, Pollok, J. M,Rogiers, X, CJocht, A, Kock, J, Blum, H. E, von Weizsacker, F, Petersen, J. Chronic infection with hepatitis B virus and antiviral drug evaluation in uPA mice after liver replication with tupaia hepatocytes. Journal of hepatology, 2005,42:54-60.
77 Rivkna, A, Rybalov, S. Chronic hepatitis B: current and future treatment options[J].Pharmacotherapy,2002,22(6):721-737.
78 Sureau, C, J.L.Romet-Lemonne, J.I.Mullins, M.Essex. Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA.Cell,1986.37-47.
79 Sells, M. A, M. L. Chen, G. Acs. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA,1987,84:1005-1009.
80 Sells, M.A, Zelent, A.Z, Shvartsman, M, Acs, G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. Journal of virology , 1988,62:2836-2844.
81 Nagahata, T, Kitagawa, M, Matsubara, K. Effect of oxetanocin G, a novel nucleoside analog, on DNA synthesis by hepatitis B virus virions. Antimicrobial agents and chemotherapy,1994,38:707-712.
82 Sekiya, K, Takashima, H, Ueda, N, Kamiya, N, Yuasa, S, Fujimura, Y, Ubasawa, M.2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl)esters as novel HBV-specific antiviral reagents. Journal of medicinal chemistry,2002,45:3138-3142.
83 Togashi, H, Ohno, S, Matsuo, T, Watanabe, H, Saito, T, Shinzawa, H, Takahashi, T.Interferon-gamma, tumor necrosis factor-alpha, and interleukin 1-beta supress the replication of hepatitis B virus through oxidative stress. Research communications in molecular pathology and pharmacology, 2000,107:407-417.
84 Tsurimoto T, Fujiyama A, Matsubara K. Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA. Proc Natl Acad Sci USA, 1987 Jan,84(2):444-448.
85 Yaginuma,K, Shirakata, Y, Kobayashi, M, Koike, K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci USA, 1987,84(9):2678-2682.
86 Ladner, S.K, Otto, M.J, Barker, C.S, Zaifert, K, Wang, G.H, Guo, J.T, Seeger, C, King,R.W. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrobial agents and chemotherapy, 1997,41:1715-1720.
87 King, R.W, Ladner, S.K, Miller, T.J, Zaifert, K. Perni, R.B, Conway, S.C, Otto, M.J.Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.Antimicrobial agents and chemotherapy, 1998,42:3179-3186.
88 Shi, J, Mathew, J.S, Tharnish, P.M, Rachakonda, S, Pai, S.B, Adams, M, Grier, J.P,Gallagher, K, Zhang, H, Wu, J.T, Shi, G, Geleziunas, R, Erickson-Viitanen, S, Stuyver,L, Otto, M.J, Watanabe, K.A, Schinazi, R.F. N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity.Antiviral chemistry & chemotherapy, 2003,14:81-90.
89 Ying, C, De Clercq, E, Nicholson, W, Furman, P, Neyts, J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, terofovir, L-FMAU, DAPD, penciclovir and lobucavir. Journal of viral hepatitis, 2000,7:161-165.
90 Gripon, P, Rumin, S, Urban, S, Le Seyec, J, Glaise, D, Cannie, I, Guyomard, C, Lucas, J,Trepo, C, Guguen-Guillouzo, C. Infection of a human hepatoma cell line by hepatitis B virus. Proceedings of the National Academy of Sciences of the United States of America,2002,99:15655-15660.
91 Gripon, P, Cannie, I, Urban, S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. Journal of virology,2005,79:1613-1622.
92 Blanchet, M. Sureau, C. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity. Journal of virology, 2006,80:11935-11945.
93 Rijntjes, P.J., Moshage, H.J, Yap, S.H. In vitro infection of primary cultures of cryopreserved adult human hepatocytes with hepatitis B virus. Virus research,1988,10:95-109.
94 Schulze-Bergkamen H,Untergasser A,Dax A,et al. Primary human hepatocytes-a valuable tool for investigation of apoptosis and hepatitis B virus infection[J]. J Hepatol,2003,38(6):736.
95 De Meyer S,Gong ZJ,Hertogs K,et al. Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on in vitro hepatitis B virus infection [J]. J Viral Hepat, 2000,7(2): 104.
96 Gripon, P, Diot, C, Guguen-Guillouzo, C. Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology, 1993,192:534-540.
97 Gripon, P, Diot, C, Theze, N, Fourel, I, Loreal, O, Brechot, C, Guguen-Guillouzo, C.Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. Journal of virology, 1988,62:4136-4143.
98 Ochiya, T, Tsurimoto, T, Ueda, K, Okubo, K, Shiozawa, M, Matsubara, K. An in vitro system for infection with hepatitis B virus that used primary human fetal hepatocytes.Proceedings of the National Academy of Sciences of the Unitied States of America, 1989，86：1 875-1 879．
99熊鸿燕，王思雄，胡小兵，等．鸭乙型肝炎病毒在鸭肝原代细胞中复制的实验观察．中国消毒学杂志，2001，18：203-207．
100 Seifer M,Heermann KH,Gerlich WH. Replication of hepatitis B virus in transfected nonhepatic cell [J]. Virology, 1990,179(1):300.
101 Tang H,McLachlan A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism [J]. Proc Natl Acad Sci USA, 2001,98 (4): 1841.
102 Delaney, W.E.t, Isom, H.C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant bacalovirus. Hepatology, 1998.1134-1146.
103 Delaney, W.E.t, Miller, T.G, Isom, H.C. Use of the hepatitis B virus recombinant baculcovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrobial agents and chemotherapy, 1999,43:2017-2026.
104 Ronni, T, Sareneva, T, Pirhonen, J, Julkunen, I. Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J Immunol, 1995,154:2764-2774.
105 Abdelhamed, A.M, Kelley, C.M, Miller, T.G, Furman, P.A, Isom, H.C. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. Journal of virology, 2002,76:8148-8160.
106 Sprinzl, M.F, Oberwinkler, H, Schaller, H, et al. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. Journal virology,2001.5108-5118.
107 Ren, S, Nassal, M. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genoma transduction with replication-defective adenovirus vectors. Journal of virology, 2001,75:1104-1116.
108 Gagneux P, M uchmore EA. The chimpanzee model: contributions and considerations for studies of hepatitis B virus [J]. Methods Mol Med,2004. 289-318.
109 Barker L F, Maynard J E, Purcell R H, et al. Hepatitis B Virus Infection in chimpanzees: titration of subtypes [J]. J Infect Dis, 1975,132(4):451- 458.
110 Bertoni R, Sette A, Sidney J, et al. Human class I supertypes and CTL repertoires extend to chimpanzees[J]. Immunology, 1998,161(8):4447.
111 Ogata N, Cote PJ, Zanetti AR, et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus[J]. Hepatology, 1999,30(3):779.
112 Wieland SF, Spangenberg HC, Thimme R, et al. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees[J]. Proc Natl Acad Sci USA,2004,101(7):2129.
113 Yan, R Q.Su, J J.Huang, D R.et al. Human hepatitis B virusand hepatocellular carcinoma I. Experimental infection of treeshrews with hepatitis B virus [J]. J cancer Res Clin Oncd,1996,122(5):283-288.
114 Zuckerman, A J.Scalise, G.M azaheri, M R.et al. Transmission of hepatitis B to the rhesus monkey [J]. Dev Biol Stand, 1975,30:236-239.
115 Scalise, G.M azaheri, M R.Kremastinou, J.et al. Transmission of hepatitis B to the rhesus monkey.Studies on the humoral and cell midiated immune response [J]. J M ed Primotal, 1978,7(2):114-118.
116 Mason WS , Aldrich C , Summers J ,et al. Asymmetric replication of duck hepatitis B virus DNA in liver cells : Free minus-strand DNA. Proc Natl Acad Sci USA, 1982,79(13):3997-4001.
117 Kock J , Schlicht HJ. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol, 1993,67 (8):4867-4874.
118 Breiner KM , Urban S , Glass B ,et al. Envelope protein mediated down regulation of hepatitis B virus receptor in infected hepatocytes. J Virol, 2001,75(1): 143-150.
119 Urban S. Binding of duck carboxypeptidase D to duck hepatitis B virus. Methods Mol Med, 2004,95:199-212.
120 TennantBC, Gerin JL. The woodchuck model of hepatitis B virus infection[J]. ILAR J,2001,42(2):89-102.
121 Chisari, F V. Pinkert, C A. M ilich, D R. et al. A transgenic mouse modelofthe chronic hepatitis B surface antigen carrierstate [J]. Science, 1985,230(4730): 1157-1160.
122 Kobayashi, M, Koike, K. Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene, 1984,30:227-232.
123 Guidotti L G,Matzke B ,Schaller H, et al. High level hepatitis B virus replication in transgenic mice. J Virol, 1995,69:6158-6161.
124 Wang Y,Cui F,Lv Y,et al. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice [J]. Hepatology, 2004,39(2):2318.
125 Liu F, Song Y, Liu D, et al. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA[J]. Gene Therapy, 1999,6(7): 1258.
126 Ketzinel-Gilad M, Zauberman A, Nussbaum O, et al. The use of hydrodynamic HBV animal model to study HBV biology and antiviral therapy[J]. Hepatol Res, 2006,34:228.
127 Wu, CH.Ouyang, EC.Walton, C.et al. Liver cell transplantation-novel animal model for human hepatic viral infections[J]. Croat Med J, 2001,42(4):446-450.